EMA, ECDC advice on fourth doses of mRNA Covid-19 vaccines
The European Centre for Disease Prevention and Control (ECDC) and European Medicines Agency’s Covid-19 task force (ETF) have concluded that it is too early to consider using a fourth dose of mRNA Covid-19 vaccines (Pfizer’s Comirnaty and Moderna’s Spikevax) in the general population, the organisations said on April 6.
However, both agencies agreed that a fourth dose (or second booster) can be given to adults 80 years of age and above after reviewing data on the higher risk of severe Covid-19 in this age group and the protection provided by a fourth dose.
The ECDC and the EMA said that there is currently no clear evidence in the EU that vaccine protection against severe disease is waning substantially in adults with normal immune systems aged 60 to 79 years and thus no clear evidence to support the immediate use of a fourth dose.
Authorities will continue to monitor data to determine if there is an increasing risk of severe illness among those who are vaccinated, the statement said.
If the current epidemiological situation changes and new signals emerge, it may become necessary to consider a fourth dose in this age group.
In the meantime, national authorities will also consider local data in deciding whether to use a fourth dose in those people at higher risk.
“For adults below 60 years of age with normal immune systems, there is currently no conclusive evidence that vaccine protection against severe disease is waning or that there is an added value of a fourth dose,” the statement said.
As re-vaccination campaigns could start in the autumn, authorities will consider the best timing for additional doses, possibly taking advantage of updated vaccines, the organisations said.
So far, no safety concerns have emerged from the studies on additional boosters.
Vaccination against Covid-19 remains the most effective way to prevent severe illness during the current pandemic, including severe illness caused by the Omicron variant, the ECDC and EMA said.
ECDC and EMA urge EU citizens to complete their schedules for both initial and booster vaccinations in line with national recommendations.
As of the end of March 2022, 83 per cent of adults in the EU had received full initial vaccinations and only 64 per cent had received a booster dose, they said.
Evidence on the effects of a fourth dose comes largely from Israel, where data indicate that a second booster given at least four months after first booster restores antibody levels without raising any new safety concerns, the ECDC and EMA said.
Data also suggest that a second booster provides additional protection against severe disease, although the duration of the benefits is not yet known and the evidence is still limited, they said.
National authorities in the EU make final decisions on the roll-out of vaccines, including booster doses, taking into account factors such as the spread of infection, the effects of Covid-19 in different populations and the emergence of new variants.
The ECDC and EMA said that they would continue to review available evidence on the effectiveness of Covid-19 vaccines and update their recommendations accordingly.
The EMA will also consider all emerging data on the safety and effectiveness of booster doses with a view to updating the product information for Covid-19 vaccines where applicable, the statement said.
(Photo: Bulgaria’s Ministry of Health)
For the rest of The Sofia Globe’s continuing coverage of the Covid-19 situation, please click here.
The Sofia Globe’s coverage of the Covid-19 situation in Bulgaria is supported by the Embassies of Switzerland and Finland.
Please support independent journalism by clicking on the orange button below. For as little as three euro a month or the equivalent in other currencies, you can support The Sofia Globe via patreon.com:
